Moderate

Chronic hepatitis B - assessment & antiviral management

Chronic HBV, tenofovir, entecavir, TAF, HBeAg, HBV DNA · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic HBV = HBsAg positive >6 months. Natural history has phases (immune-tolerant, immune-active/HBeAg+ or HBeAg-, inactive carrier, resolved). Antiviral nucleos(t)ide analogues suppress viral replication, reduce progression to cirrhosis and hepatocellular carcinoma. Treatment decision depends on ALT, HBV DNA level, HBeAg status, fibrosis stage, and special situations.

Red flags

  • Decompensation: jaundice, ascites, encephalopathy, coagulopathy (urgent - avoid entecavir issues; do not interferon)
  • Acute-on-chronic flare with rising bilirubin/INR
  • Suspected HCC (rising AFP, liver mass)
  • HDV coinfection (more aggressive disease)
  • Reactivation during immunosuppression (rising ALT/HBV DNA)

Assessment

Differential diagnosis

  • Hepatitis C / D coinfection (test HDV in all HBsAg positive)
  • MASLD/MASH or alcohol as cause of raised ALT
  • Autoimmune hepatitis
  • Drug-induced liver injury
  • Acute vs chronic HBV (IgM anti-HBc, clinical course)
  • HBV reactivation (immunosuppression/chemotherapy)

Investigations

  • HBsAg, anti-HBs, HBeAg/anti-HBe, HBV DNA (quantitative), HBV genotype if needed
  • Anti-HDV (hepatitis D) in all HBsAg positive; HIV and HCV serology; anti-HAV immunity
  • LFTs (ALT trend), FBC, INR, U&E, AFP
  • Fibrosis staging: transient elastography (FibroScan) +/- biopsy; APRI/FIB-4
  • Liver USS - baseline and HCC surveillance
  • Pregnancy test / HBV DNA in pregnancy (maternal viral load for transmission risk)

Management

  • Confirm chronicity (HBsAg >6 months) and determine phase from ALT, HBV DNA, HBeAg, fibrosis
  • Assess fibrosis (FibroScan/FIB-4) and screen for cirrhosis
  • Treat if: cirrhosis (ANY detectable HBV DNA), or immune-active disease (elevated ALT with elevated HBV DNA), or significant fibrosis/inflammation; treat regardless of ALT in specific groups (pregnancy with high viral load, immunosuppression, extrahepatic disease, family history HCC) [verify local thresholds]
  • Start a high-barrier nucleos(t)ide analogue (entecavir, tenofovir DF, or tenofovir alafenamide) - choose by renal/bone profile, pregnancy, HIV status, prior therapy
  • Give antiviral PROPHYLAXIS to any HBsAg+ (or anti-HBc+) patient before immunosuppression/chemotherapy/rituximab to prevent reactivation
  • Vaccinate against hepatitis A; counsel on transmission and vaccinate contacts; alcohol avoidance
  • Enrol in HCC surveillance (6-monthly USS +/- AFP) if cirrhosis or other high-risk (see HCC surveillance protocol)
  • Monitor on-treatment: HBV DNA, ALT, renal function/phosphate; treatment is usually long-term/indefinite

Drugs & doses

Tenofovir disoproxil fumarate (TDF) 245 mg PO once daily (monitor renal function and phosphate; preferred in pregnancy)
Tenofovir alafenamide (TAF) 25 mg PO once daily (better renal/bone profile - prefer if osteoporosis/renal impairment)
Entecavir 0.5 mg PO once daily (1 mg if lamivudine-experienced or decompensated cirrhosis); take on empty stomach
Pregnancy with HBV DNA >200,000 IU/mL: tenofovir DF from ~28 weeks to reduce vertical transmission (plus neonatal HBIG + vaccine)
HBV reactivation prophylaxis (pre-immunosuppression): entecavir or tenofovir, continue during and >=6-12 months after (longer for rituximab) [verify local]
Avoid lamivudine/adefovir monotherapy (low genetic barrier, resistance)
Pegylated interferon alfa (finite course, selected HBeAg+ non-cirrhotic) - specialist only

Disposition

Outpatient hepatology/specialist. Admit for decompensation, severe flare, or suspected HCC. Lifelong monitoring; antiviral therapy usually indefinite.

Complications & pitfalls

  • Cirrhosis and portal hypertension
  • Hepatocellular carcinoma (can occur even without cirrhosis in HBV)
  • Hepatic decompensation / acute-on-chronic liver failure
  • HBV reactivation with immunosuppression (can be fatal)
  • Hepatitis D superinfection
  • Extrahepatic: polyarteritis nodosa, membranous glomerulonephritis

Exam pearls

  • AASLD/IDSA 2025 & WHO 2024: preferred first-line agents are entecavir, tenofovir DF, or TAF - all high-barrier; avoid lamivudine monotherapy.
  • Give antiviral PROPHYLAXIS before any immunosuppression/chemotherapy/rituximab in HBsAg+ (and consider in anti-HBc+) patients - reactivation can be fatal. [verify local]
  • HBV causes HCC even WITHOUT cirrhosis - maintain surveillance in high-risk groups (Asian/African, family history, older age).
  • Test every HBsAg+ patient for hepatitis D (anti-HDV), HIV and HCV, and vaccinate against hepatitis A.
  • In pregnancy with high maternal viral load, tenofovir DF from third trimester plus neonatal HBIG and vaccine dramatically cuts vertical transmission. Exact DNA and ALT treatment thresholds [verify local guideline].

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.